Background We conducted a randomized, placebo-controlled, double-blind trial to determine
whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival in non–…

… cure in up to 16% of patients with stage III lung cancer [6]. Despite modest improvement in
survival and symptom relief provided by systemic therapy, … rash in erlotinib-treated lung cancer …

… Symptom improvement in lung cancer patients treated with erlotinib: quality of life
analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. …

… Erlotinib and gefitinib, two small molecular agents that target the tyrosine kinase domain of
the EGFR, were approved in many countries for the treatment … erlotinib, as first-line treatment …

… Erlotinib is a small molecule inhibitor of epidermal growth … with previously treated advanced
non-small cell lung cancer. Here, … trial of erlotinib (Tarceva Lung Cancer Survival Treatment). …

… erlotinib in patients with HER1/EGFR-expressing non–small-cell lung cancer previously treated
… The current study was planned to estimate the objective tumor response rate of erlotinib …

… -cell lung cancer who received erlotinib after other treatments had failed. Women, Asians,
patients with adenocarcinoma, and patients who had never smoked were more likely than …

… The EGFR is frequently expressed in a variety of epithelial tumors; non-small-cell lung
cancer (NSCLC) is among the epithelial cancers that are characterized by a generally high …

… Purpose: Erlotinib has proven activity in pretreated patients with advanced non–small cell
lung cancer (NSCLC). We evaluated erlotinib in the frontline treatment of advanced NSCLC …

… Erlotinib (Tarceva) is a specific epidermal growth factor … Gefitinib (Iressa) shares with
erlotinib both a common chemical … as a third-line therapy for non-small cell lung cancer (NSCLC) …